What is it about?
Bacteria are becoming resistant to all known antibiotics, including antibiotics of last resort called the polymyxins. There is a structurally comparable class of antibiotics, called the octapeptins, which work against bacteria that have become resistant to the polymyxins. The review discusses how they differ from the polymyxins in their activity and how they work, despite looking very similar.
Featured Image
Why is it important?
We need new antibiotics - if we don't find ones against the bacteria that have become resistant to all current antibiotics, we face a return to a 'pre-antibiotic era'. The octapeptins may represent a new class of antibiotics, but there is some skepticism since they look very similar to the polymyxins, old antibiotics that have quite a few liabilities. Excitingly, the octapeptins work against polymyxin-resistant bacteria, and do not cause resistance to emerge as quickly as the polymyxins, so look very promising.
Perspectives
We are working to find new and improved versions of the original octapeptins, and are making some exciting progress. This review attempts to highlight the potential benefits of this new class of antibiotics and dispel the perception that they are just another polymyxin.
Mark Blaskovich
University of Queensland
Read the Original
This page is a summary of: Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?, Expert Review of Anti-infective Therapy, June 2018, Taylor & Francis,
DOI: 10.1080/14787210.2018.1483240.
You can read the full text:
Contributors
The following have contributed to this page
